Quantcast

Latest Morphotek Inc. Stories

2009-03-02 08:00:00

EXTON, Pa., March 2 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma.

2008-09-25 09:00:54

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc., a privately held Los Angeles-based biotechnology company developing oncology products, today announced they have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr.

2008-08-26 09:00:28

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study.

2008-08-13 09:00:13

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers.

2008-07-24 09:01:13

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that Rodney Dausch, Vice President and Chief Financial Officer (CFO), received the Philadelphia Business Journal/Drexel University's LeBow College of Business Small Company CFO of the Year Award.


Word of the Day
obdormition
  • Sleep; the state or condition of being asleep.
  • The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.
The word 'obdormition' comes from a Latin word meaning "to fall asleep".
Related